A Phase 3 interventional study of Inotuzumab ozogamicin (INO) and Blinatumomab in B-Cell Acute Lymphoblastic Leukaemia, sponsored by Charite University, Berlin, Germany. Recruiting at 21 sites in 21 countries. Open to participants aged 1 Year and older. Per ClinicalTrials.gov, last updated 2026-10-26.
Sponsored by Charite University, Berlin, Germany · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies testing Inotuzumab Ozogamicin in Burkitt Lymphoma — 7 open to participants now, 12 under way, 3 of them phase 3. Inotuzumab Ozogamicin · Burkitt Lymphoma.
Among the 18 studies testing Inotuzumab Ozogamicin in Burkitt Lymphoma, this one is the 2nd largest by planned enrollment, is the only one that started in 2026, is one of 3 in phase 3, reaches primary completion later than 11 of the 11 other live ones, and was the 17th registered.
978 studies on the registry are indexed under Burkitt Lymphoma; 160 are open to participants now.
Browse Burkitt Lymphoma studies →7 of the 18 studies testing Inotuzumab Ozogamicin in Burkitt Lymphoma are open now, in 12 countries. Recruiting first, the newest first:
Sunil G. Iyer · Sites in United States
Ages 18+
Children's Oncology Group · Sites in United States, Australia, Canada and 2 more countries
Ages 365 days–25 yrs
National Cancer Institute (NCI) · Sites in United States, Puerto Rico
Ages 18+
Alliance for Clinical Trials in Oncology · Sites in United States, Canada
Ages 18–39
M.D. Anderson Cancer Center · Sites in United States
Ages 14+
By country, each count listing its studies:
Inotuzumab Ozogamicin: first FDA approval 2017 (BESPONSA), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →
Of the 132 Burkitt Lymphoma studies recruiting now, 41 (31%) set no upper age limit and 78 (59%) stop at 75 or younger; 75 take children under 18; 2 take healthy volunteers.
This study: 1 Year and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 10 · Phase 3 3
First in 2010; this study’s year is marked. 1 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 750 is above the median of 36 across 767 interventional studies indexed under Burkitt Lymphoma.
Median enrollment 59 across the 18 interventional studies. Of the 5 that completed or were terminated, 3 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 18 has an industry lead sponsor. The 10 most frequent:
Charite University, Berlin, Germany is the lead sponsor of 857 studies on the registry; 128 are open to participants now.
Charite University, Berlin, Germany has 1 study filed under Burkitt Lymphoma — fewer than ten, so there is no comparison to draw.
5 of the studies testing Inotuzumab Ozogamicin in Burkitt Lymphoma that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03150693Phase 3Alliance for Clinical Trials in OncologyInotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia | 2027-11-01 |
| NCT02981628Children's Oncology GroupInotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia | 2026-12-31 |
| NCT03739814National Cancer Institute (NCI)Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia | 2027-02-01 |
| NCT03441061M.D. Anderson Cancer CenterInotuzumab Ozogamicin in Treating Patients With B-cell Acute Lymphocytic Leukemia With Positive Minimal Residual Disease | 2027-02-28 |
| NCT05303792Alliance for Clinical Trials in OncologyComparing Inotuzumab Combined With Low Intensity Chemotherapy Plus Blinatumomab to Usual Chemotherapy Plus Blinatumomab in Older Adults With CD22+ B-cell Acute Lymphoblastic Leukemia | 2027-04-01 |
Add all 5 to your calendar (.ics) → With an account.
Among the 18 studies testing Inotuzumab Ozogamicin in Burkitt Lymphoma, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The IntReALL BCP 2020 study aims to review recent developments and findings regarding chemoimmunotherapy with inotuzumab and immunotherapy with blinatumomab and to increase the use of promising new immunotherapeutic drugs as replacements for toxic SOC chemotherapy elements.
The IntReALL BCP 2020 study has the potential to improve CR and EFS rates for all SR and HR groups, as well as for patients with IEM recurrence, by replacing toxic chemotherapy with targeted, less toxic immunotherapy strategies, and could establish these new approaches as SOC for children with relapsed BCP ALL in the future.
Though survival of children with acute lymphoblastic leukemia (ALL) has considerably improved over the past few decades, relapsed ALL remains a leading cause of mortality in children with cancer. Prognostic factors for patients with relapsed ALL are duration of first remission, immunophenotype of the malignant clone, site of relapse, molecular response to induction therapy (i.e minimal/measurable residual disease, MRD) and very high risk genetic features. The prognosis of patients with relapsed ALL was substantially improved with intensive multidrug chemotherapy and allogeneic hematopoietic stem cell transplantation (allo-HSCT) in the majority of patients at the cost of acute and long-term toxicity, including early and late treatment-related deaths. Patients with precursor B-cell (BCP) ALL classified as standard risk (SR) with late isolated bone marrow (BM) or combined with extramedullary (EM) disease and without high risk genetic features achieve high remission rates (> 95%) and favorable event-free survival (EFS) rates (65%) with conventional consolidation and maintenance chemotherapy if, after induction therapy, the leukemia could be reduced below the MRD level of 10-3 or 10-4, depending on the induction regimen. About 50% of SR patients experience poor MRD response after conventional chemotherapy induction and require intensified consolidation through allo-HSCT with total body irradiation to achieve EFS rates comparable to that of SR patients with good MRD response. Patients classified as high risk (HR) with early BM/EM relapse still demonstrate poor CR rates of around 65-75% being treated on standard induction therapy, and high rates of subsequent relapse. Consequently, these patients all require allo-HSCT for consolidation of 2nd remission. Patients with isolated extramedullary relapse (IEM) had a better outcome with CNS directed induction / consolidation chemotherapy as provided with the ALL-REZ BFM backbone compared to conventional induction as provided with the ALL-R3 induction. Patients with very high risk (VHR) genetic features (KMT2A::AFF1, TCF3::PBX1, TCF3::HLF rearrangements, low hypodiploidy/near haploidy, TP53 alterations) and/or very early relapses (i.e. those occurring within 18 month after initial diagnosis) have a limited benefit from conventional chemotherapy followed by allo-HSCT since their EFS rates have been reported to be below 20%.
For SR and HR patients, there is a need to replace toxic induction/consolidation chemotherapy with targeted less toxic drugs and to improve the rates of MRD negative remission after induction. In SR patients, reduction of MRD after induction could result in a lower proportion of patients with indication for allo-HSCT, a treatment that - despite being efficacious - is associated with substantial long-term sequelae. For SR patients, there is a medical need to reduce toxic consolidation and maintenance chemotherapy with targeted less toxic and potentially more effective treatment. The CD3/19 directed bi-specific monoclonal antibody blinatumomab has shown better efficacy and less toxicity compared to conventional consolidation chemotherapy in children with relapsed B-cell precursor (BCP) ALL with and without extramedullary involvement in randomized trials. The superiority of blinatumomab has been shown for HR patients before receiving HSCT in a randomized trial in Europe and for HR/IR patients before receiving HSCT and SR patients with MRD good response in a randomized trial conducted by the Children's Oncology Group. In SR patients with MRD good response, a total of 3 courses of Blinatumomab has been applied partly replacing consolidation chemotherapy and partly as add on to the standard therapy. Thus, blinatumomab can be considered as best standard of care (SOC) for early consolidation in this indication. Blinatumomab is currently being developed for subcutaneous administration. This formulation is planned to be tested in phase I/II studies in children with BCP ALL at the end of 2025. Innovative, more efficacious therapies, such as CD19-targeting CAR T cells, are urgently needed for VHR patients, since conventional therapies, including allo-HSCT, have led to dismal results.
Inotuzumab ozogamicin (InO) is a CD22 directed humanized monoclonal antibody linked to the toxin calicheamicin, belonging to the class of antibody-drug conjugate (ADC). CD22 is expressed on nearly all BCP-ALLs. After antigen binding, InO is internalized and the toxin released causing DNA damage and inducing apoptosis. InO has shown high MRD negative remission rates compared to SOC in adult and pediatric patients with relapsed/refractory BCP ALL and a safe and effective dose has been identified in a pediatric phase I/II trial.
The trial IntReALL BCP 2020 aims at integrating these recent developments and findings and at increasing the use of promising new immune-therapeutic drugs replacing toxic SOC chemotherapy elements. SR patients with bone marrow relapse will randomly receive the SOC induction ALLR3 with Mitoxantrone or InO monotherapy. Post induction, they will receive a 1st consolidation chemotherapy element (SCB1). Patients with MRD good response (\< 10-4) will receive 3 courses of blinatumomab during consolidation and maintenance therapy, the 1st replacing the consolidation chemotherapy element SCB2, the 2nd added on after the 3rd consolidation chemotherapy element SCB3, and the 3rd added on after the 4rth consolidation element SCB4 and 8 weeks of conventional maintenance therapy, which, at difference of the IntReALL 2010 trial will not include vincristine/dexamethasone pulses. SR patients with MRD poor response will receive SCB1 and one blinatumomab course followed by allo-HSCT. During the course of the trial, the protocol is planned to be amended changing the blinatumomab formulation from IV to SC as soon as the latter becomes available. .
HR patients with bone marrow relapse will be included into an industry sponsored induction window trial and will join the academic IntReALL BCP 2020 study only for consolidation, since all HR patients have an indication for allo-HSCT. HR patients in CR2 after induction will receive one course of consolidation chemotherapy (HC1), one course of blinatumomab as recently established SOC followed by allo-HSCT. Whereas for the European Blina-215 trial (randomized blinatumomab versus HC3) 2 courses HC1 and HC2 were given as standard early consolidation, in the COG trial (AALL1331) the whole consolidation chemotherapy has been replaced by blinatumomab. One standard chemotherapy consolidation course HC1 is considered as feasible compromise and provides time for B-cell regeneration after InO as prerequisite for T-cell expansion during the blinatumomab consolidation course.
Patients with IEM will receive the IntReALL SR2010 arm A backbone with blinatumomab replacing the chemotherapy element SCA3 as bridge to allo-HSCT in those with early relapse or to further consolidation therapy in those with late relapse.
The hypotheses addressed within the IntReALL BCP 2020 trial are, that:
The IntReALL BCP 2020 trial has the potential to improve CR and EFS rates for all SR and HR groups, as well as in patients with IEM relapse, by replacing toxic chemotherapy with targeted less toxic immunotherapy strategies and may establish these new approaches as SOC for children with relapsed BCP ALL in future. In addition, the IntReALL BCP 2020 trial has the ambition to reduce the proportion of SR patients in need of an allograft for consolidation therapy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
For all study questions:
Specific for SR induction randomization:
Specific for SR MRD poor response consolidation:
Specific for SR MRD good response consolidation:
Specific for IEM arm:
Exclusion Criteria:
Patients with any concurrent medical condition, laboratory abnormality, concomitant treatment, or comorbidity that, in the investigator's clinical judgment would
Specific for SR induction randomization:
Specific for blinatumomab treatment:
Allowed systemic diseases and concomitant medication
Prohibited medication
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
prospective, randomized 1:1, open label phase II/III trial comparing arm AI (ALLR3-MITOX) versus arm BI (InO). Randomization is stratified according to frontline treatment group (BFM, AIEOP, ALLTogether, other) and localization of relapse (BM+CNS, other)
Drug: Inotuzumab ozogamicin (INO)
single arm trial with 3 courses of blinatumomab, the 1st replacing the consolidation chemotherapy element SCB2, the 2nd added on after the consolidation chemotherapy element SCB3, and the 3rd added on after the consolidation element SCB4 and 8 weeks of conventional maintenance therapy, then followed by conventional maintenance therapy being applied without reinduction chemotherapy pulses until week 132, as compared to historical controls (IntReALL BCP 2020 SR SOC induction arm compared with IntReALL SR 2010 arm B without epratuzumab)
Drug: Blinatumomab
single arm trial with HC1 and 1 course of blinatumomab followed by allo-HSCT compared with historical controls
Drug: Blinatumomab
single arm trial with the IntReALL SR 2010 Arm A (ALL-REZ BFM 2002) including blinatumomab replacing the chemotherapy element SCA3 compared with historical controls. SR patients will receive further conventional consolidation, local irradiation and maintenance, HR patients will be given allo-HSCT after blinatumomab
Drug: Blinatumomab
Antibody Drug Conjugate (Inotuzumab)
Also known as: InO vs. R3 randomisation in SR
Bispecific t-cell enganger BiTE
Also known as: Blinatumumab vs. historical control
SR induction EFS
timespan of survival until endpoint relevant event (nonresponse, death in remission, relapse, secondary malignancy) or until end of follow up
Time frame: From enrollment until 2 years after end of treatment
SR-MRD good response consolidation DFS
timespan of survival after achievnemt of eremission until endpoint relevant event (death in remission, relapse, secondary malignancy) or until end of follow up
Time frame: From enrollment until 2 years after end of treatment
HR with CR2 consolidation DSF
timespan of survival after achievnemt of eremission until endpoint relevant event (death in remission, relapse, secondary malignancy) or until end of follow up
Time frame: From enrollment until 2 years after end of treatment
Isolated extramedullary manifestations: EFS
timespan of survival until endpoint relevant event (nonresponse, death in remission, relapse, secondary malignancy) or until end of follow up
Time frame: From enrollment until 2 years after end of treatment
SR induction: Pharmacokinetics Inotuzumab
cumulative area under the concentration-time curve (AUC)
Time frame: from enrollment until day 28
SR induction: MRD
MRD negativity rate after induction quantified by flow- and/or PCR techniques
Time frame: Day 28 of induction
SR-MRD good response consolidation: OS
timespan of survival until death or until end of follow up
Time frame: From enrollment until 2 years after end of treatment
Isolated extramedullary manifestations: EFS
timespan of survival until endpoint relevant event (nonresponse, death in remission, relapse, secondary malignancy) or until end of follow up
Time frame: From enrollment until 2 years after end of treatment
SR induction: allo-HSCT
Proportion of patients requiring allo-HSCT
Time frame: week 14 to 20 after enrollment
SR induction: OS
timespan of survival until death or until end of follow up
Time frame: from enrollment until 2 years after end of treatment
SR induction: Toxicity
Toxicity (assessed by CTCAE grades and SAE reports)
Time frame: from enrollement until end of protocol therapy
SR induction: CD19 positive cells
Rate of patients with CD19 positive cells after SCB1 prior to Blinatumomab
Time frame: week 9 after enrollment
SR-MRD good response consolidation: Toxicity
Toxicity (quantified by CTCAE grades and SAE reports)
Time frame: from enrollment until end of treatment (week 132)
Isolated extramedullary manifestations: OS
timespan of survival until death or until end of follow up
Time frame: from enrollment until 2 years after end of treatment
Isolated extramedullary manifestations: DFS by MRD
timespan of survival after achievnemt of eremission until endpoint relevant event (death in remission, relapse, secondary malignancy) or until end of follow up by MD after induction (cut-off 10-4)
Time frame: from enrollment until 2 years after end of treatment
HR with CR2 consolidation: OS
timespan of survival until death or until end of follow up
Time frame: from enrollment until 2 years after end of treatment
HR with CR2 consolidation: Toxicity
Toxicity (assessed by CTCAE grades and SAE reports)
Time frame: from enrollment until end of treatment (day 100 post HSCT)
HR with CR2 consolidation: MRD
MRD negativity rates before allo-HSCT quantified by flow- and/or PCR techniques
Time frame: week 13 after enrollment
HR with CR2 consolidation: allo-HSCT
allo-HSCT rates
Time frame: week 14 after enrollment
Inotuzumab PK
Maximum and through concentrations of inotuzumab
Time frame: from enrollment until end of induction (day 28), before and 1 hour after start of inotuzumab infusion
Inotuzumab PK exposure response relationship
CR- and MRD negativity rates by inotuzumab AUC
Time frame: from enrollment until end of induction (day 28)
Plan to share: No
Started Sep 2026 (actual). Primary completion is estimated for Mar 2033, 78 months after the start.
Of 19 phase 3 interventional studies under Burkitt Lymphoma, half reached primary completion within 106 months of starting (the median), counting those still running; a quarter within 78 and three quarters within 119. This study's planned 78 months is below that.
Start moved once since we started tracking on Sep 25, 2026: Apr 2026 → Sep 2026, on Oct 26, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Inotuzumab Ozogamicin · Blinatumomab
Charite University, Berlin, Germany →